Zurich, 19 January 2021 – Achiko AG (SWX:ACHI, ISIN CH0522213468) has published the notice regarding an Extraordinary Shareholders’ Meeting at 10:00 a.m. (CET) on 11 February 2021 in Zurich.Due to the Covid-19 pandemic, this Extraordinary Shareholders’ Meeting will be held in accordance with … [Read more...]
Achiko strengthens leadership team with
new President and new SVP Commercialisation
Appoints new President, biotechnology research scientist and entrepreneur Dr. Morris S. BerrieAppoints new SVP Commercialisation, business leader in life science Richard LingardNew senior leadership expected to drive production and commercialisation for Gumnuts, Achiko’s test kit for … [Read more...]
Achiko completes share capital increase
Zurich, 11 December 2020 – Achiko AG (SWX:ACHI, ISIN CH0522213468) announces that its share capital recorded in the commercial register has been increased by 3,034,187 shares to 105,831,805 shares to satisfy claims from a convertible note previously issued by the Company. The new shares have … [Read more...]
Achiko partners with Udayana University for Covid-19 testing research in Bali, Indonesia
Achiko signed a research agreement with Udayana University’s Research Department to study the practicability of a mass testing approach with Teman Sehat and Gumnuts when availableThe Study will focus on a systems approach to mass testing and consequences to healthcare, and consumer and business … [Read more...]
Achiko AG enters into a convertible note of up to CHF 2m with Negma Group
Zurich, 30 November 2020 – Achiko AG (SWX:ACHI, ISIN CH0522213468) (“the Company”) has entered into a new subordinated convertible loan transaction of up to CHF 2 million with Negma Group containing a conversion right into registered shares of the Company with a conversion period of 3 years.The … [Read more...]